MM Guidelines 2010
MM Guidelines 2010
MM Guidelines 2010
1.
2.
3.
4.
5.
206-987-7777
206-987-2041
206-598-4606
206-598-4070
206-987-6255
206-987-2113
206-987-3371
206-987-2632
206-987-2210
206-987-2184
Background: These guidelines, based on a combination of evidence, expert opinion and clinical
experience, are intended to assist healthcare providers to provide optimal care to babies with
myelomeningocele, as well as pregnant women carrying fetuses with myelomeningocele. In addition,
several SCH policies address the surgical and nursing management of patients with
myelomeningocele. These complementary documents are located in the hospital policy section of the
CHILD website at SCH.
Most fetuses with myelomeningocele and hydrocephalus are now recognized by prenatal diagnosis.
Ideally, women carrying fetuses with myelomeningocele should receive prenatal counseling from both
an obstetrician/perinatologist and a postnatal provider experienced in the care of babies with
myelomeningocele. The SCH NDV program provides comprehensive prenatal counseling for
myelomeningocele through the SCH Prenatal Diagnosis and Treatment Program (206-987-6255). This
counseling includes information on the pathophysiology of myelomeningocele, the MOMS trial of in
utero closure surgery, the expected pregnancy course, the recommended delivery route, associated
medical complications, medical/surgical treatment, recurrence risk, prevention with high-dose folic acid
and prognosis with respect to mobility, cognition, bladder/bowel function, independence and quality of
life. When appropriate, reproductive decision-making support is provided.
While not universally accepted, our program feels that cesarean section delivery prior to rupture of
membranes improves motor outcomes for fetuses with lumbosacral lesions that protrude >1cm off the
back and expectation of somewhat intact lower extremity motor function. Cesarean section is unlikely
to be of benefit after rupture of membranes, for fetuses with flat lesions and for fetuses without lower
extremity movement.
All newborns with myelomeningocele benefit from sterile management and preparation for closure of
their open lesions within 24 to 48 hours of birth. A serious breach of sterility may be a reason to defer
surgical treatment, although this is rare. The presence of other life-threatening anomalies may be
reason to defer treatment indefinitely.
As of February 2003, a national multicenter randomized trial of in utero versus postnatal
myelomeningocele repair began recruiting patients. Three centers around the country are involved in
the study (Vanderbilt, Childrens Hospital of Philadelphia, and University of California at San Francisco).
No other center in the US will provide in utero repair outside the randomized trial. Participants are
(Guidelines for Management of Newborns with Myelomeningocele Dr. Doherty Rev. 5/2010)
delivered by C-section without a trial of labor at one of the study sites. For more details, see the study
website: www.spinabifidamoms.com.
Fetuses with skin-covered lesions such as lipomeningoceles or myelocystoceles do not routinely
require cesarean section delivery. Such fetuses can often be recognized by the absence of any brain
involvement (no hydrocephalus, no Chiari II malformation), the location and characteristics of the mass
itself and/or the presence of abdominal wall defects such as exstrophy of the cloaca that do not occur
with myelomeningocele. Negative amniotic alpha fetoprotein (AFP) and/or acetylcholinesterase testing
can also distinguish skin covered lesions.
Neonates with skin-covered lesions do not need to be managed under sterile conditions and usually do
not require immediate neurosurgical repair. Neurosurgery and Neurodevelopmental should be
consulted about these infants who may require additional work-up and/or monitoring for neurogenic
bowel and bladder. Neurosurgical intervention usually occurs at 4-8 months of age, unless there is
progressive neurological impairment. Recurrence risk for isolated skin covered lesions tends to be
lower than for myelomeningocele and folic acid supplementation is not preventive.
1) Guidelines for the obstetric provider who is the first to become aware of a patient carrying a
fetus with myelomeningocele
; Ensure that the patient is offered appropriate diagnostic work-up including serial ultrasounds to
confirm the defect and evaluate for other findings as well as amniocentesis for karyotype, AFP
and acetylcholinesterase.
; Ensure that the patient receives appropriate counseling, ideally from both an
obstetrician/perinatologist and a postnatal provider experienced in the care of babies with
myelomeningocele. The SCH NDV program (usually Dr. Doherty) provides comprehensive
prenatal counseling for myelomeningocele through the SCH Prenatal Diagnosis and Treatment
Program (206-987-6255).
; Ensure that medical records, imaging, and laboratory data are made available to the consultants
2) Guidelines for UW/SCH faculty providing prenatal counseling
; Provide counseling regarding the pathophysiology of myelomeningocele, the MOMS trial of in
utero closure surgery, the expected pregnancy course, the recommended delivery route,
associated medical complications, medical/surgical treatment, recurrence risk, prevention with
high-dose folic acid and prognosis with respect to mobility, cognition, bladder/bowel function,
independence and quality of life. When appropriate, provide reproductive decision-making
support.
; Usually, counseling is performed through the Prenatal Diagnosis and Treatment Program in the
Springbrook Professional Center near SCH (206) 987-6255. The Prenatal Program staff have
experience coordinating prenatal and postnatal care and can assist in all tasks described in this
section.
; Upon completion of the prenatal counseling session, the patient will be added by the Prenatal
Clinic staff to the Prenatal Forecast Tool. The Forecast Tool is a spreadsheet distributed
electronically every Monday to provider groups, including the NDV attendings, NDV clinic
nurses, Neurosurgery ARNPs, MCC Service ARNPs, MCC Service Medical Director, NICU
charge nurses, and neonatologists. The Forecast Tool contains the pregnant womans SCH
MR#, anticipated delivery date, delivery hospital, delivery route, fetal findings, prenatal consult
date and provider name.
; If the delivery date is not known at the time of prenatal consultation, contact the Prenatal Clinic
at 206-987-6255 once delivery date is finalized. The date will be added to the Forecast Tool.
; If the child will be delivered within three working days, contact the attendings on call for
Neurosurgery, NDV and Neonatology by phone, in addition to notifying the Prenatal Clinic.
(Guidelines for Management of Newborns with Myelomeningocele Dr. Doherty Rev. 5/2010)
; Ensure that OT/PT has been consulted and notified by phone at the Infant OT/PT Team
Referral Line 206-987-2113.
; Notify the NDV nurses at 206-987-2184. The NDV nurses can provide the floor staff nurses with
consultation and instructions as to the infants needs.
Evaluation:
; Examine the infant for other malformations and syndromes that could affect the prognosis or
management plan.
; Record information about lower extremity muscle strength and sensory level.
; Discuss the management plan with the medical team.
Social:
; Spend adequate time with family to discuss overall care, answer questions and develop a
therapeutic alliance.
; Confirm that the family has been given: 1) Living with Spina Bifida: A Guide for Families and
Professionals book by Adrian Sandler, MD (University of North Carolina Press), 2) the
Hydrocephalus pamphlet published by the Hydrocephalus Association, 3) a SCH Care
Notebook and 4) the NDV folder with additional information about myelomeningocele. If parents
do not have these items, notify the NDV nurses or social worker who can provide them.
; Confirm that social work is involved. For families who may qualify based on income, encourage
application for SSI (Supplemental Security Income) as soon as possible.
Neurogenic bladder:
; An indwelling catheter is preferred during the acute post-closure period and may be required
beyond that time in certain clinical situations.
; Clean intermittent catheterization (CIC) should be implemented 2-3 times daily, as soon as the
patient is stable enough. A true post-void residual is obtained by CIC within a few minutes of a
detected void and should be less than 5cc. Random CIC volumes should be less than 30cc.
; Parents should be trained to perform CIC, as early as possible since children may be
discharged home on CIC.
; Urology consultation should occur prior to discharge.
; Prophylactic antibiotics, Ditropan and phenoxybenzamine are not be routinely used in the
bladder management of newborns with myelomeningocele.
Hydrocephalus:
; Monitor daily head size, plotted on an appropriate head-size chart and ensure that follow-up
cranial ultrasounds are performed (typically twice weekly in unshunted infants). In premature
infants, the brain is more compliant so the ventricles may expand with little change in head size.
; For patients with shunts, ensure appropriate positioning to prevent skin breakdown over the
shunt valve or chamber (have a doughnut under the head.)
Other:
; Ensure that nutrition has been consulted to optimize nutritional status.
; Ensure that a neonatal hearing evaluation is performed.
; If the patient has club feet or other musculoskeletal abnormalities, confirm that outpatient
orthopedic follow-up is scheduled prior to discharge.
; Give recommendations about discharge needs (such as catheters) and outpatient NDV followup.
; Notify the NDV/Birth Defects patient care coordinators, preferably in writing or by e-mail, of the
plan for clinic appointments. These appointments need to be tailored to the needs of each
infant and family. Work with the discharge planners and others unfamiliar with our clinic to
minimize uncoordinated appointments in many separate clinics.
For questions or feedback on this document, please contact Dan Doherty and/or Bill Walker. In
addition, any of the following faculty will be glad to answer questions about specific patients: Jeff
(Guidelines for Management of Newborns with Myelomeningocele Dr. Doherty Rev. 5/2010)
McLaughlin, William Walker, Chuck Cowan, Dan Doherty, Gwen Glew or Sam Zinner. Contact the
SCH paging operator (206-987-2000) to determine who is on call.
Doctor
Chuck Cowan
Dan Doherty
Gwen Glew
Jeff McLaughlin
William Walker
Samuel Zinner
Phone Number
206-987-2210
206-987-2210
206-987-2210
206-987-2210
206-987-2210
206-685-1290
Pager Number
206-469-5369
206-540-5892
206-469-0668
206-469-6704
206-469-3579
206-469-5157
Email Address
charles.cowan@seattlechildrens.org
dan.doherty@seattlechildrens.org
gwen.glew@seattlechildrens.org
john.mclaughlin@seattlechildrens.org
william.walker@seattlechildrens.org
szinner@u.washington.edu
Disclaimer: These guidelines have been developed by the Division of Developmental Medicine,
Department of Pediatrics, UW, to assist physicians and other healthcare professionals. The
recommendations may not be appropriate for use in all circumstances, and any decision to
adopt a particular recommendation must be made by the practitioner based upon available facts
and circumstances presented by individual patients.
Distribution:
Developmental Medicine attendings, nurses, fellows, PCCs
Developmental Medicine website c/o CHDD webmanager
Neurosurgery attendings, ARNPs, residents, PCCs
Neonatology: Dr. Craig Jackson & website
NICU head nurse, SCH
NICU head nurse, UW
Prenatal Diagnosis and Treatment Program, SCH
Maternal and Infant Care Clinic, UW
SCH Housestaff office and website
OT/PT Department, SCH
Director, Surgery, SCH: Dr. Robert Sawin
(Guidelines for Management of Newborns with Myelomeningocele Dr. Doherty Rev. 5/2010)